Aura Biosciences, Inc. (AURA)Healthcare | Biotechnology | Boston, United States | NasdaqGM
6.24 USD
-0.10
(-1.577%) ⇩
(Oct. 16, 2026, 11:51 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:24 a.m. EDT
The long-term outlook is catastrophic for a traditional equity investor. The business has suffered a relentless, multi-year decline, dropping nearly 60% over the last three years with zero positive annual returns in that window. This is not a temporary setback; the market has consistently punished the stock every single year, signaling deep structural issues or a failing business model. While the balance sheet currently shows low debt relative to assets, the company is burning significant cash, and the negative earnings and return metrics confirm a deteriorating enterprise. The recent capital raise is a classic distress signal, forcing existing shareholders to dilute their holdings to keep the lights on. Short-term, the situation remains precarious. The stock is trading below its 50-day moving average, and the statistical forecast offers no help, predicting a slight downward drift with low confidence. The options market reflects this apathy with virtually no activity, meaning there is no speculative fuel to drive a sudden reversal. Without a credible catalyst to arrest the bleeding or reverse the multi-year trend, the risk-reward profile is heavily skewed against buyers. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.072902 |
| AutoETS | 0.073531 |
| AutoARIMA | 0.073695 |
| MSTL | 0.074169 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 1.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.164 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.263 |
| Market Cap | 647,117,952 |
| Forward P/E | -3.07 |
| Beta | 0.41 |
| Website | https://www.aurabiosciences.com |
As of Oct. 10, 2026, 6:24 a.m. EDT: Speculator positioning is extremely thin and non-directional. Call volume and open interest are negligible across expirations, with no significant strikes indicating a bullish bet. Put activity is similarly sparse, with minimal open interest at key strikes. The lack of meaningful volume or open interest suggests a vacuum of speculative conviction rather than a specific directional view.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11816573 |
| Address1 | 80 Guest Street |
| Address2 | 5th Floor |
| All Time High | 26.16 |
| All Time Low | 4.345 |
| Ask | 9.22 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,056,540 |
| Average Daily Volume3 Month | 795,878 |
| Average Volume | 795,878 |
| Average Volume10Days | 1,056,540 |
| Beta | 0.413 |
| Bid | 5.18 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.047 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.24 |
| Current Ratio | 16.821 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.35 |
| Day Low | 6.1 |
| Debt To Equity | 5.263 |
| Display Name | Aura Biosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -136,992,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.557 |
| Enterprise Value | 350,242,496 |
| Eps Forward | -2.03 |
| Eps Trailing Twelve Months | -1.75 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.0094 |
| Fifty Day Average Change | -0.7694001 |
| Fifty Day Average Change Percent | -0.1097669 |
| Fifty Two Week Change Percent | 11.816573 |
| Fifty Two Week High | 9.535 |
| Fifty Two Week High Change | -3.295 |
| Fifty Two Week High Change Percent | -0.34556898 |
| Fifty Two Week Low | 4.73 |
| Fifty Two Week Low Change | 1.5099998 |
| Fifty Two Week Low Change Percent | 0.31923884 |
| Fifty Two Week Range | 4.73 - 9.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,514,200,000 |
| Float Shares | 74,643,610 |
| Forward Eps | -2.03 |
| Forward P E | -3.0738916 |
| Free Cashflow | -56,323,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 113 |
| Fullday Change | -0.10000038 |
| Fullday Change Percent | -1.577293 |
| Fullday Price | 6.24 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02434 |
| Held Percent Institutions | 0.95808 |
| Implied Shares Outstanding | 103,704,809 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts. |
| Long Name | Aura Biosciences, Inc. |
| Market | us_market |
| Market Cap | 647,117,952 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_100249028 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -131,011,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 623,265,902 |
| Number Of Analyst Opinions | 5 |
| Open | 6.31 |
| Operating Cashflow | -103,007,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 617 500 8864 |
| Previous Close | 6.34 |
| Price Hint | 2 |
| Price To Book | 2.047916 |
| Profit Margins | 0.0 |
| Quick Ratio | 16.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.10000038 |
| Regular Market Change Percent | -1.577293 |
| Regular Market Day High | 6.35 |
| Regular Market Day Low | 6.1 |
| Regular Market Day Range | 6.1 - 6.35 |
| Regular Market Open | 6.31 |
| Regular Market Previous Close | 6.34 |
| Regular Market Price | 6.24 |
| Regular Market Time | 1,792,165,895 |
| Regular Market Volume | 213,728 |
| Return On Assets | -0.31238002 |
| Return On Equity | -0.53485 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,704,809 |
| Shares Percent Shares Out | 0.1 |
| Shares Short | 10,366,122 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,203,498 |
| Short Name | Aura Biosciences, Inc. |
| Short Percent Of Float | 0.100600004 |
| Short Ratio | 11.87 |
| Source Interval | 15 |
| State | MA |
| Symbol | AURA |
| Target High Price | 23.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 16.6 |
| Target Median Price | 15.0 |
| Total Cash | 323,840,000 |
| Total Cash Per Share | 3.123 |
| Total Debt | 16,594,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.6572 |
| Two Hundred Day Average Change | -0.4172001 |
| Two Hundred Day Average Change Percent | -0.062669 |
| Type Disp | Equity |
| Volume | 213,728 |
| Website | https://www.aurabiosciences.com |
| Zip | 2,135 |